Alimera Sciences, Inc.
$2.0M 3,868 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
PolyNovo North America LLC
PolyNovo North America LLC reported $1,956,571.67 across General Payments, Research, and Ownership to 5,925 physicians and teaching hospitals across 7,446 transactions.
- $2.0M
- All-tracks total
- 7,446
- Transactions
- 5,925
- Recipients
- +$697.6K
- General Payments vs PY2023
PolyNovo North America LLC reported $1,956,571.67 across all CMS Open Payments tracks (General + Research + Ownership) to 5,925 physicians and teaching hospitals in Program Year 2024 - ranking #453 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $827,702.00, averaging $330.22 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer polynovo-north-america-llc PolyNovo North America LLC
$2.0M · #453/1,925 · 0.0% industry · PY2024
- TOT $2.0M
- RANK #453
- SHARE 0.0%
- TXN 7,446
- RCP 5,925
- CAT 4
- GEN $827.7K
- ΔGEN +$697.6K
- TOP1 11.0%
- PY 2024
Volume peers
Nearest volume peer: Alimera Sciences, Inc. ($2.0M)
PolyNovo North America LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
PolyNovo North America LLC's CMS-reported General Payments increased by $697.6K (+536.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: POLYNOVO NORTH AMERICA LLCPY2023: POLYNOVO NORTH AMERICA LLCPY2024: PolyNovo North America LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $130,141.87
- PY2024
- $827,702.00
What the Data Shows for PolyNovo North America LLC
$1,956,571.67: that is what PolyNovo North America LLC reported in payments to 5,925 physicians and teaching hospitals during Program Year 2024, spread across 7,446 transactions ($262.77 per transaction, $330.22 per recipient). The company sits at rank #453 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
5,810 transactions worth $408.0K make "Food and Beverage" the top general-payment category in the 4-category breakdown below, 49.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads PolyNovo North America LLC's 4-category general-payment breakdown at $408.0K, 49.3% of the reported total.
PolyNovo North America LLC reports 4 general-payment categories - the top three are Food and Beverage (49.3%), Consulting Fee (43.8%), and Travel and Lodging (6.5%). The remaining 1 category make up 0.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How PolyNovo North America LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $408.0K | 5,810 | 49.3% |
| Consulting Fee | $362.5K | 69 | 43.8% |
| Travel and Lodging | $53.8K | 43 | 6.5% |
| Compensation for Faculty or Speaker (Medical Education) | $3.4K | 3 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $288,531.76 (34.9%) of $827,702.00 in this company's General Payments records across 3,382 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for PolyNovo North America LLC
The five named recipients with the highest reported General Payments from this company
- 1
Shaun Mendenhall
$90,718.27 across 48 reported transactions
- 2
Paul Kim
$72,808.75 across 27 reported transactions
- 3
Kyle Chepla
$61,175.96 across 29 reported transactions
- 4
Mark S Granick
$33,828.78 across 16 reported transactions
- 5
William Hickerson
$30,000.00 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as PolyNovo North America LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about PolyNovo North America LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with PolyNovo North America LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Grifols USA, LLC
$2.0M 23,281 recipients
Compare payment profiles
Ferring Pharmaceuticals Inc.
$2.0M 21,199 recipients
Compare payment profiles
CooperSurgical, Inc.
$1.9M 9,542 recipients
Compare payment profiles
PROCEPT BioRobotics Corporation
$1.9M 8,013 recipients
Compare payment profiles
Biohaven Pharmaceutical Holding Company Ltd.
$2.0M 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.